Genetic Determinations of Variable Responsiveness to Clopidogrel and Implications for Neurointerventional Procedures
Authors:
- 1 January 2012
- journal article
- review article
- Published by S. Karger AG in Interventional Neurology
- Vol. 1 (1) , 22-30
Abstract
Endovascular intervention is emerging as a substitute for open surgical procedures for the treatment of cerebrovascular disease. However, up to 9% of patients undergoing neurointerventional procedures develop thromboembolic complications. Strategies to reduce periprocedural thromboembolic events are dominated by the use of dual antiplatelet therapy (DAT) which has been validated based on studies of peripheral vascular and coronary intervention. Of note, DAT decreases adverse vascular outcomes by 75–80% in patients undergoing percutaneous coronary intervention (PCI). It follows that similar treatment effects would be observed in neurointerventional populations. However, a growing body of evidence demonstrates that a subgroup of patients respond suboptimally to DAT, and in particular to clopidogrel (termed clopidogrel hyporesponders). These patients may be at an increased risk of thromboembolic complications such as in-stent thrombosis following neurointerventional procedures. Previous studies report 5–30% suboptimal response to clopidogrel in the cardiovascular population, while a higher prevalence is seen in populations undergoing neurointerventional procedures, i.e. as much as 66%. Knowledge of the mechanism leading to clopidogrel hyporesponsiveness is accumulating. A number of genetic polymorphisms, in particular CYP 2C19*2, have been associated with clopidogrel hyporesponsiveness and clinical outcomes. In addition, there are significant differences in the prevalence of CYP 2C19*2 across racial groups. Approximately 50% of Asians and 25% of Caucasians harbor the CYP 2C19*2 allele. While no prospective randomized trials currently exist to demonstrate improved clinical outcomes with genotype-based treatment for carriers of the CYP 2C19*2 polymorphism, a number of studies show that an increased dose of clopidogrel improves platelet inhibition in hyporesponders. The aim of the review is to examine the current understanding of the genetic basis of clopidogrel hyporesponsiveness in patients undergoing neurointerventional procedures and to explore current efforts using genotype and phenotype testing as well as alternative strategies to overcome the clopidogrel hyporesponsiveness.Keywords
This publication has 30 references indexed in Scilit:
- Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and TiclopidineClinical Pharmacology & Therapeutics, 2010
- Genetic variability in response to clopidogrel therapy: clinical implicationsEuropean Heart Journal, 2010
- Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching TherapiesCirculation, 2010
- Anti-Platelet Drug Resistance in the Prediction of Thromboembolic Complications after NeurointerventionJournal of Korean Neurosurgical Society, 2010
- Clopidogrel non-responsiveness and risk of cardiovascular morbidityThrombosis and Haemostasis, 2010
- Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventionsEuropean Heart Journal, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of ClopidogrelJACC: Cardiovascular Interventions, 2008
- Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center ExperienceAmerican Journal of Neuroradiology, 2008
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998